FDA approves HemoCleanse lung cancer study
This article was originally published in Clinica
HemoCleanse and IDT have received approval from the FDA to begin a feasibility study of HemoCleanse's BioLogic-HT system for whole-body hyperthermia treatment for metastatic non-small cell lung cancer. The treatment involves elevating body temperature to control or destroy viruses and other heat sensitive organisms and HemoCleanse believes it may increase the effectiveness of chemotherapy. The study will be conducted at the University of Texas Medical Branch at Galveston, Texas.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.